Oxford, United Kingdom, 07 March, 2022: Orbit Discovery (Orbit), a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to all therapeutic targets, including those previously considered “undruggable,” today announced the selection of its lead product development candidate, FOG-001, a first-and-only-in-class direct β-catenin inhibitor. FOG-001 represents the first of FogPharma’s proprietary, conformationally hyperstabilized α-helical polypeptides (Helicon polypeptides), a new class of therapeutics designed to combine the targeting strength and specificity of antibodies with the broad tissue distribution, intracellular target engagement and oral dosing optionality of small molecules.
RALEIGH, NC / ACCESSWIRE / February 28, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today an update on its late stage pipeline products vurolenatide, a proprietary long-acting glucagon-like peptide (GLP-1) agonist in a Phase 2 trial for adults with short bowel syndrome (SBS), and larazotide, a gut-selective tight junction modulator in a Phase 3 trial for celiac disease.
In contrast to the major families of small molecules and antibodies, cyclic peptides, as a family of synthesizable macromolecules, have distinct biochemical and therapeutic properties for pharmaceutical applications. Cyclic peptide-based drugs have increasingly been developed in the past two decades, confirming the common perception that cyclic peptides have high binding affinities and low metabolic toxicity as antibodies, good stability and ease of manufacture as small molecules. Natural peptides were the major source of cyclic peptide drugs in the last century, and cyclic peptides derived from novel screening and cyclization strategies are the new source. In this review, we will discuss and summarize 18 cyclic peptides approved for clinical use in the past two decades to provide a better understanding of cyclic peptide development and to inspire new perspectives. The purpose of the present review is to promote efforts to resolve the challenges in the development of cyclic peptide drugs that are more effective.
DOI: 10.1039/D1CB00154J (Review Article) RSC Chem. Biol., 2022, 3, 18-31
RALEIGH, NC / ACCESSWIRE / February 25, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the publication of encouraging data in the journal Critical Care Explorations, accessible online here, on the use of larazotide to treat pediatric patients with multisystem inflammatory syndrome in children (MIS-C) resulting from COVID-19. MIS-C is a rare but severe and potentially life-threatening condition that usually develops in children weeks to months after they have experienced a mild or even asymptomatic case of COVID-19.
HARRISON, N.Y., Jan. 6, 2022 /PRNewswire/ -- Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced today the initiation of Phase 2 and dosing of the first patient in the glioblastoma (GBM) expansion cohort in the ongoing Phase 1-2 Study of ST101.
The expansion cohorts in the study include patients with refractory, locally advanced and metastatic cutaneous melanoma, hormone-receptor-positive breast cancer, castrate-resistant prostate cancer, and GBM, and are designed to determine proof-of-concept efficacy of ST101 and provide further insights into safety, pharmacokinetics (PK) and pharmacodynamics (PD).
Novo Nordisk, the Danish drug maker on Thursday announced the launch of oral semaglutide in India for treatment of type 2 diabetes.
The oral semaglutide will cost Rs 315 per pill or around Rs 10000 for a full month treatment.
"We have kept it at the (similar) price range of the injectable GLP-1, not only that we have followed price equilibrium band, which means if a person goes from 3 mg to 7 mg, the cost they pay is just 9-10% higher, and not double, as per conventional models ..
VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs, including both proprietary diagnostic tools, enabling the early and timely identification of severe sepsis, as well as broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections. The Company announces that its novel antibiofilm peptide technology is in advanced development through its collaboration with its pre-clinical partner, iFyber, LLC, and grant funding from the United States Army Medical Research and Materiel Command (USAMRMC)1.
Dear Friends and Colleagues,
We are looking forward to our upcoming peptide symposium in Boulder and having an opportunity to greet many of you in person. In order to enhance the safety of all our visitors the organizers have finalized a COVID policy for all guests.
As part of this policy, proof of COVID-19 vaccination is required to attend the symposium in person. This information will be required at time of check in and can be in the form of a government issued vaccination card, mobile app, or image of paper documentation. Individuals who are not vaccinated, even for religious or medical reasons, will not be allowed to attend the symposium.
The Meienhofer Award was established in 2007 to annually recognize an individual with a lifetime of achievement in peptide science. The award is named after Johannes Meienhofer, in honor of his transformative discoveries in solid phase peptide synthesis. Notably, Meienhofer's work demonstrated the power of medicinal chemistry in peptide pharmacology and is considered to have laid the foundation of modern synthetic peptide therapeutics.
This year's recipient is Dr. Sam Gellman, the Ralph F. Hirschmann Professor of Chemistry and Vilas Research Professor at the University of Wisconsin - Madison. He earned his A.B. from Harvard University in 1981 and his Ph.D. from Columbia University, under Ronald Breslow, in 1986. After an NIH post-doctoral fellowship at the California Institute of Technology, with Peter Dervan, Gellman joined the faculty at the University of Wisconsin - Madison in 1987. Major interests in Gellman's program involve polypeptides in diverse forms and settings. Specific topics include fundamental studies of non-covalent interactions, elucidation of the origins of peptide and protein folding preferences, development and application of unnatural peptidic oligomers that display protein-like conformational behavior ("foldamers"), creation of new amphiphiles for membrane protein manipulation, and development of biologically active polymers. The work from Gellman’s laboratory has been recognized by the Vincent du Vigneaud Award and Rao Makineni Lectureship from the American Peptide Society, and by the Arthur C. Cope Scholar Award, the Ralph F. Hirschmann Award in Peptide Chemistry and the Ronald Breslow Award in Biomimetic Chemistry from the American Chemical Society. Gellman is a Fellow of the American Academy of Arts & Sciences and a Member of the National Academy of Science.
Dr. Gellman will receive his award Tuesday, Sept. 24 during the Boulder Peptide Symposium. Register today!
More information on the Meienhofer Award, including a list of previous recipients, and the Boulder Peptide Symposium can be found online at www.boulderpeptide.org/meienhofer-award.